A user's experience with hair loss and their consideration of using finasteride, minoxidil, RU58841, stemoxydine, fluridil, and peptide serum with redensyl as treatment options.
The conversation discusses using ecklonia cava as a natural alternative to finasteride for hair loss. Users share their experiences and opinions on its effectiveness.
The user has been using finasteride for 6 months and minoxidil for 12 months to address hair loss and recently started estradiol monotherapy for additional benefits. They are unsure if their hair is regrowing and are seeking advice on their progress.
Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
A user shared their successful hair loss treatment using RU58841, topical minoxidil, and microneedling, noting significant improvement over three months. They chose RU58841 over finasteride due to personal preference and reported no side effects, while others discussed their experiences with different treatments and supplements.
The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.
The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.
The user has been managing hair loss with microneedling, Nutrafol, topical finasteride/minoxidil foam, LLLT, and Nizoral, and plans to add oral minoxidil. They are seeing improvement and are cautious about using oral finasteride due to past gynecomastia concerns.
A 31-year-old uses Minoxidil, RU58841, Reviv Hair Serum, and Ketoconazole shampoo for hair loss but avoids finasteride. They plan to reintroduce red light therapy (LLLT) and Eucapil despite previous shedding concerns.
Exosomes are discussed as a new hair loss treatment, but skepticism is expressed about their effectiveness. Other treatments mentioned include Minoxidil, finasteride, and RU58841.
The user reports potential hair regrowth after using finasteride nightly, minoxidil twice daily, occasional microneedling, and vitamin supplements, and is considering RU58841 in the future. Replies suggest they are seeing improvement.
The user is using topical minoxidil twice daily for hair regrowth and is hesitant to use finasteride due to concerns about hormonal effects. The conversation includes mixed opinions on the effectiveness of the treatment and suggestions to use a DHT blocker for better results.
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.
Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.
2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.
Hair cloning claims by Dr. Gho are widely considered a scam, with skepticism about the effectiveness of his hair stem cell transplantation. Users suggest that if it were effective, wealthy individuals would opt for it over traditional methods like FUE transplants.
AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.
A 22-year-old is frustrated with ongoing hair loss despite using treatments like topical minoxidil, finasteride, microneedling, oral dutasteride, and oral minoxidil. Their dermatologist suggests treating scalp inflammation with oral tretinoin and using exosomes for alopecia.
A user who has had positive results from using a regimen of microneedling, finasteride, minoxidil, peppermint oil, keto shampoo and DHT organic shampoo for hair growth. The conversation also addressed whether to use .5mg or 1mg of finasteride and the difference between dermapens and rollers.
RU58841 users discuss increasing dosage for better hair regrowth, with some considering adding minoxidil and finasteride. Users report mixed results, with some experiencing side effects at higher doses.
A user successfully regrew hair using 1mg Finasteride daily, 5% topical Minoxidil 1-2 times a day, and weekly derma stamping, with no side effects. Others shared their hair loss struggles and interest in these treatments.
Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.
A 20-year-old saw significant hair regrowth after 9 months of using DHT blockers (finasteride and dutasteride) and 6 months of hormone replacement therapy (HRT) with estradiol. The regrowth is attributed to low testosterone and high estradiol levels, without using Minoxidil.
Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.